Laser Speckle Contrast Imaging for Cutaneous Microvascular Dysfunction Detection in Systemic Sclerosis.

NCT ID: NCT01743612

Last Updated: 2016-06-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

101 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-01-31

Study Completion Date

2015-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the study is to determine if postocclusive hyperemia of palmar and dorsal face of the hand with Laser speckle contrast imaging discriminate between patients with systemic sclerosis, subjects with primary Raynaud's phenomenon and healthy subjects.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Microvascular dysfunction is a key event in the pathogenesis of systemic sclerosis. There are currently no test measuring it in clinical practice. Response to humeral occlusion is interesting and this response has been studied with laser Doppler flowmetry. More recently, laser imaging has been used analysing the granularity of the laser: laser Speckle Contrast Imaging which allow combining high temporal resolution to high spatial resolution.

The investigators proposed, in this study, to compare this imaging at basal and after post-occlusive hyperaemia of dorsal and palmar face of hand in 3 groups: healthy subjects, primary Raynaud's phenomenon and systemic sclerosis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Raynaud Disease Scleroderma, Systemic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sclerodermic patients

patients with systemic sclerosis according to Leroy's classification

Group Type EXPERIMENTAL

laser speckle contrast imaging

Intervention Type PROCEDURE

blood flow recording during 30 minutes after 2 post-occlusive hyperaemia of 5 minutes separated by 30 minutes.

Cooling

Intervention Type PROCEDURE

blood flow of the hand recording during 30 minutes in a cooling-box

Primary Raynaud's phenomenon

without secondary disease

Group Type EXPERIMENTAL

laser speckle contrast imaging

Intervention Type PROCEDURE

blood flow recording during 30 minutes after 2 post-occlusive hyperaemia of 5 minutes separated by 30 minutes.

Cooling

Intervention Type PROCEDURE

blood flow of the hand recording during 30 minutes in a cooling-box

Healthy subjects

18 years old or more

Group Type EXPERIMENTAL

laser speckle contrast imaging

Intervention Type PROCEDURE

blood flow recording during 30 minutes after 2 post-occlusive hyperaemia of 5 minutes separated by 30 minutes.

Cooling

Intervention Type PROCEDURE

blood flow of the hand recording during 30 minutes in a cooling-box

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

laser speckle contrast imaging

blood flow recording during 30 minutes after 2 post-occlusive hyperaemia of 5 minutes separated by 30 minutes.

Intervention Type PROCEDURE

Cooling

blood flow of the hand recording during 30 minutes in a cooling-box

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy subjects:
* Man ou woman 18 years old or more.
* Without Raynaud's phenomenon or systemic sclerosis.

Raynaud's phenomenon subjects:

* Man ou woman 18 years old or more.
* with primary Raynaud's phenomenon.

Systemic sclerosis:

* Man ou woman 18 years old or more.
* systemic sclerosis in accordance to Leroy's classification.

Exclusion Criteria

* active digital ulceration
* Bosentan, iloprost ou sildenafil treatment
* History of axillary dissection , trauma or surgery
* history of thromboembolic disease or thrombophilia
* minor or law-protected major
* exclusion period in another study
* No affiliation to medicare
* pregnant, parturient or breasting woman
* concomitant serious disease: progressive cancer, liver failure, history of myocardial infarction less than 5 years, angor
* smoking in the 6 last months
* person deprived of liberty by a legal or administrative decision, person under legal protection
* maximal annual indemnification reached.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Grenoble

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jean-Luc CRACOWSKI, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

CIC, CHU Grenoble

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Clinical Research Center

Grenoble, , France

Site Status

Vascular Medical Unit

Grenoble, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

References

Explore related publications, articles, or registry entries linked to this study.

Gaillard-Bigot F, Roustit M, Blaise S, Gabin M, Cracowski C, Seinturier C, Imbert B, Carpentier P, Cracowski JL. Abnormal amplitude and kinetics of digital postocclusive reactive hyperemia in systemic sclerosis. Microvasc Res. 2014 Jul;94:90-5. doi: 10.1016/j.mvr.2014.05.007. Epub 2014 Jun 2.

Reference Type DERIVED
PMID: 24990822 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

DCIC 11 25

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Echo Systemic Sclerosis
NCT03143413 UNKNOWN